What is the clinical evidence from this study?

Study design: Cohort. Population: Mobile aortic atheroma and systemic emboli (n=31). Intervention: Warfarin vs. No warfarin. Primary outcome: Vascular events (p=0.006).

What question did this study set out to answer?

This study aims to assess how plaque morphology and the use of warfarin affect the risk of recurrent embolic events in patients with mobile aortic atheroma.

July 6, 2026Journal of the American College of Cardiology

Mobile Aortic Atheroma and Systemic Emboli: Efficacy of Anticoagulation and Influence of Plaque Morphology on Recurrent Stroke

View Full Paper

Ask AI

Bookmark

Key result

Warfarin linked to ~89% fewer vascular events in patients with mobile aortic atheroma.

P=0.006
n=31

Why the study?

Does warfarin anticoagulation reduce recurrent embolic or vascular events in patients with systemic emboli and mobile aortic atheroma?

Key Points

This study aims to assess how plaque morphology and the use of warfarin affect the risk of recurrent embolic events in patients with mobile aortic atheroma.
Thirty-one patients with mobile aortic atheroma and a history of systemic embolic events were recruited.
Patients were categorized based on the size of mobile atheroma and followed for vascular events and anticoagulation use.
Dimensions of atheroma components were measured, including height, width, and area to classify atheromas into three size groups.
Patients not receiving warfarin experienced a higher incidence of vascular events (45% vs. 5%, p = 0.006).
27% of patients not on warfarin had strokes, while none treated with warfarin did (p = 0.04).
The annual incidence of stroke in non-warfarin patients was 0.32, with 18% experiencing myocardial infarction.

Study Design

Type

Cohort (n=31)

Structured PICO

Does warfarin anticoagulation reduce recurrent embolic or vascular events in patients with systemic emboli and mobile aortic atheroma?

Population

31 patients presenting with a systemic embolic event and mobile aortic atheroma, followed up for recurrent embolic or vascular events.

Exposure

Warfarin anticoagulation

Comparator

No warfarin anticoagulation

Outcome

Recurrent embolic or vascular events (including stroke and myocardial infarction)hard clinical

Main Result

Absolute Event Rate: 5% vs 45%

p-value: p=0.006

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Warfarin anticoagulation significantly reduces the risk of recurrent stroke and vascular events in patients with systemic emboli and mobile aortic atheroma, regardless of the size of the mobile atheroma component.

Cite This Study

Dressler et al. (1998) conducted a cohort in Mobile aortic atheroma and systemic emboli (n=31). Warfarin vs. No warfarin was evaluated on Vascular events (p=0.006). Warfarin anticoagulation was associated with a significantly lower incidence of vascular events compared to no warfarin (5% vs. 45%, p=0.006) in patients with mobile aortic atheroma.

synapsesocial.com/papers/6a4b7310f318da06943cd5ee https://doi.org/10.1016/s0735-1097(97)00449-x

View Full Paper

Ask AI

Bookmark

Mobile Aortic Atheroma and Systemic Emboli: Efficacy of Anticoagulation and Influence of Plaque Morphology on Recurrent Stroke

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Mobile Aortic Atheroma and Systemic Emboli: Efficacy of Anticoagulation and Influence of Plaque Morphology on Recurrent Stroke

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider